These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28899815)

  • 1. Blockage of regulatory T cells augments induction of protective immune responses by influenza virus-like particles in aged mice.
    Wen Z; Wang X; Dong K; Zhang H; Bu Z; Ye L; Yang C
    Microbes Infect; 2017 Dec; 19(12):626-634. PubMed ID: 28899815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities.
    Hodgins B; Pillet S; Landry N; Ward BJ
    PLoS One; 2019; 14(1):e0210009. PubMed ID: 30629622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch.
    Quan FS; Kim YC; Song JM; Hwang HS; Compans RW; Prausnitz MR; Kang SM
    Clin Vaccine Immunol; 2013 Sep; 20(9):1433-9. PubMed ID: 23863506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
    Ramirez A; Morris S; Maucourant S; D'Ascanio I; Crescente V; Lu IN; Farinelle S; Muller CP; Whelan M; Rosenberg W
    Vaccine; 2018 Feb; 36(6):873-880. PubMed ID: 29306508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection induced by early stage vaccination with pandemic influenza virus-like particles.
    Lee GJ; Quan FS
    Vaccine; 2016 Jul; 34(33):3764-72. PubMed ID: 27317263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    Quan FS; Huang C; Compans RW; Kang SM
    J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
    Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
    Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.
    Herbert AS; Heffron L; Sundick R; Roberts PC
    Virol J; 2009 Apr; 6():42. PubMed ID: 19393093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
    Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
    Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of gamma-irradiation conditions on the immunogenicity of whole-inactivated Influenza A virus vaccine.
    David SC; Lau J; Singleton EV; Babb R; Davies J; Hirst TR; McColl SR; Paton JC; Alsharifi M
    Vaccine; 2017 Feb; 35(7):1071-1079. PubMed ID: 28109709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
    Liu WC; Liu YY; Chen TH; Liu CC; Jan JT; Wu SC
    Antiviral Res; 2016 Sep; 133():110-8. PubMed ID: 27491439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.
    Wodal W; Schwendinger MG; Savidis-Dacho H; Crowe BA; Hohenadl C; Fritz R; Brühl P; Portsmouth D; Karner-Pichl A; Balta D; Grillberger L; Kistner O; Barrett PN; Howard MK
    PLoS One; 2015; 10(2):e0113963. PubMed ID: 25719901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice.
    Chang H; Duan J; Zhou P; Su L; Zheng D; Zhang F; Fang F; Li X; Chen Z
    Microbes Infect; 2017 Dec; 19(12):616-625. PubMed ID: 28899814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.